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Purpose: Inflammation is central in disease pathophysiology and accurate methods for its detection and
quantification are increasingly required to guide diagnosis and therapy. Here we explored the ability of
Fast Field-Cycling Magnetic Resonance (FFC-MR) in quantifying the signal of ultra-small superparamag-
netic iron oxide particles (USPIO) phagocytosed by J774 macrophage-like cells as a proof-of-principle.
Methods: Relaxation rates were measured in suspensions of J774 macrophage-like cells loaded with
USPIO (0–200 lg/ml Fe as ferumoxytol), using a 0.25 T FFC benchtop relaxometer and a human whole-
body, in-house built 0.2 T FFC-MR prototype system with a custom test tube coil. Identical non-
imaging, saturation recovery pulse sequence with 90 flip angle and 20 different evolution fields selected
logarithmically between 80 lT and 0.2 T (3.4 kHz and 8.51 MHz proton Larmor frequency [PLF] respec-
tively). Results were compared with imaging flow cytometry quantification of side scatter intensity
and USPIO-occupied cell area. A reference colorimetric iron assay was used.
Results: The T1 dispersion curves derived from FFC-MR were excellent in detecting USPIO at all concen-
trations examined (0–200 lg/ml Fe as ferumoxytol) vs. control cells, p  0.001. FFC-NMR was capable of
reliably detecting cellular iron content as low as 1.12 ng/mg cell protein, validated using a colorimetric
assay. FFC-MR was comparable to imaging flow cytometry quantification of side scatter intensity but
superior to USPIO-occupied cell area, the latter being only sensitive at exposures  10 mg/ml USPIO.
Conclusions: We demonstrated for the first time that FFC-MR is capable of quantitative assessment of
intra-cellular iron which will have important implications for the use of USPIO in a variety of biological
applications, including the study of inflammation.
 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tissue inflammation is a recognised disease process in many
cardiovascular conditions, whether it involves the myocardiumor the arterial vascular wall [1]. Inflammatory cell tracking with
imaging in vivo is likely to become part of an individualised diag-
nostic pathway, assessing the severity of disease and monitoring
the response to anti-inflammatory therapies. Inflammatory macro-
phages are particularly well suited for MR imaging due to their
strong phagocytic ability to uptake contrast agents such as ultra-
small superparamagnetic iron oxide (USPIO) particles [2]. Phagocy-
tosed USPIOs are retained in inflammatory cells after the intra-
vascular pool is cleared. Due to their superparamagnetic proper-
ties, USPIOs internalised by macrophages can be tracked with Mag-
netic Resonance Imaging (MRI) techniques in vivo [3]. The dipolar
relaxivity describes the effect a contrast agent on proton relaxation
rate in a homogenous medium, and is defined by
2 H. Abbas et al. / Journal of Magnetic Resonance 313 (2020) 106722R1,2 = R01,2 + r1,2. C (where R1,2 is the R1 or R2 proton relaxation rate
in the presence of the contrast agent. R01,2 are the relaxation rates in
the absence of the contrast agent, r1,2 are the relaxivities in s1
mM1 and C is the contrast agent concentration) [4].
USPIOs have a 10-fold (or higher) stronger effect on T2 relax-
ivity than gadolinium in clinical scanners [4] and have potential
for detection at much lower concentration. They create large
magnetic field distortions which affect nearby water molecules
and shorten T2* therefore creating regions of signal loss [5].
Detection has been achieved at routine clinical magnetic fields
(1.5 and 3 T) using T2* sequences [6]. T1-relaxivity can also be
higher than in gadolinium, which in turn can vary as a function
of field strength, core size and degree of particle aggregation
(15–25 s1 mM1 in water at clinical field range) [7,8]. By com-
parison the r1 of gadolinium chelates is fairly constant at clinical
field strengths (approx. 4 s1 mM1). Our group has previously
imaged myocardial inflammation in humans using USPIO during
acute stress-induced cardiomyopathy [9]. Uptake of USPIO in
infarcted myocardium has been previously demonstrated in a
clinical experiment with focus on T2* effects at 3 T [10]. Patients
with distinct mural uptake of USPIO within abdominal aortic
aneurysms (AAA) had a 3-fold higher growth rate, suggesting that
cellular inflammation may predict AAA expansion and thus risk of
rupture [11]. Similarly USPIO-enhanced MRI of carotid plaque can
be used to detect ruptured or rupture-prone atherosclerotic
lesions [12,13].
Experiments on infarcted human myocardium have shown that
R2* (1/T2*) increases from a baseline of 41.0 ± 12.0 s1 to
155 ± 45.0 s1 at 3 T, 24 h following administration of USPIO,
which demonstrates an extremely short T2* with a narrow
dynamic range in this application (approx. 6–24 ms) [10].
There has been a tendency over the years to increase the mag-
netic fields strengths to enhance image resolution and improve
signal-to-noise ratio (SNR). However, the T1 values of different tis-
sues tend to converge at higher field strengths (>1.5 T), causing the
endogenous T1 contrast to diminish [14]. The relaxivity of most
exogenous contrast agents used to overcome this problem is also
dependent on magnetic field strength, tending to be lower at
higher field strengths [15–19]. USPIO may therefore add better
value in low-field imaging systems. Therefore, an exploration into
the field-dependency of USPIO contrast in biological media
becomes a prerequisite to targeting low-field MRI devices for these
applications. The use of USPIO as a contrast agent in low field MRI
has only been recently reported [20] and in such regimes USPIOs
are efficient T1 contrast agents thanks to their superparamagnetic
properties [19]. Yin et al have more recently demonstrated strong
T1 enhancement with 18 nm diameter USPIO at ultra-low field
(0.13mT), with longitudinal relaxivity in solution (deionised water)
of r1 = 615 s1 mM1, two orders of magnitude higher than typical
Gd-based preparations at clinical fields (1.5–3 T) [21]. The
enhanced R1 at low field was attributed to the coupling of proton
spins with SPIO nanoparticle magnetic fluctuations (Brownian
and Néel) with a low frequency peak in the imaginary part of AC
susceptibility (v00). Therefore, a low magnetic field device may
have distinct advantages in assessing the presence and intensity
of the inflammatory response, by accurately detecting and quanti-
fying the uptake of such inflammation-tracking USPIO contrasts.
The high T1 signal at low field may also reduce imaging time and
the non-toxic, biocompatibility of USPIO may be more welcome
than nephrotoxic Gd-based agents.
Here we propose to exploit USPIOs as a T1 contrast agent for
tissue inflammation using Fast Field-Cycling Nuclear Magnetic
Resonance (FFC-NMR) at magnetic fields below 0.25 T in an effort
to better understand how this contrast agent may be used in
low-field systems. Beyond the advantages of a fixed low magneticfield, a field-cycling device may also allow the discrimination of
USPIO contribution from other sources of relaxation due to its abil-
ity to delineate and quantify the ferromagnetic peak on the 1/T1
dispersion profile of USPIO [22,23].
Our group is at the forefront of developing Fast Field-Cycling
Magnetic Resonance Imaging (FFC-MRI) for medical applications
[24,25]. FFC-MRI is an imaging modality using the principles of
FFC-NMR, which measures the longitudinal nuclear magnetic res-
onance relaxation time (T1) as a function of the magnetic field
strength (B0) and allows access to T1 over a range of magnetic
fields. The systems used in our labs allow accessing low magnetic
fields from 20mT to 250 mT. These measurements are then pro-
cessed to provide the field dispersion of R1 (where R1 = 1/T1), also
called the R1 dispersion profile. It is well-known that R1 varies
greatly between biological tissues [26,27] and can therefore be
exploited for diagnostic applications. FFC-NMR pulse sequences
typically comprise three periods, polarisation, evolution and
detection, during which different magnetic fields are applied
(B0P, B0E and B0D respectively). Polarisation increases the signal
amplitude for improved contrast, evolution generates the field-
dependant evolution that is needed to extract R1 dispersion infor-
mation and detection is used to measure the NMR signal to be
processed. Crucially, signal detection measurements are always
carried out at the same magnetic field, B0D, so that the resonant
frequency cB0D remains the same throughout the experiment
(where c is the gyromagnetic ratio of the nuclear spin system
studied).
In this work we hypothesized that FFC-NMR is capable of
detecting and quantifying the superparamagnetic signal of USPIO
phagocytosed by cells with a sensitivity comparable to validated
techniques of iron quantification in biological samples, such as
standard colorimetric assays. We also compare FFC-NMR with
the imaging flow cytometric features of USPIO-laden cells.2. Methods
2.1. Cell preparation
Murine BALB/c J774A.1 macrophage-like cells (Sigma-Aldrich,
ECACC code 91051511, no mycoplasma detectable microscopi-
cally) were cultured in DMEM (Gibco, Cat # 11960044) supple-
mented with 1 mM L-glutamine (Gibco, Cat # 25030081), 1%
penicillin/streptomycin (Gibco, Cat # 15140122) and 10% foetal
bovine serum (Gibco, Cat # 12676029) at 37 C with 5% CO2. For
iron loading, cells plated at 1x106 cells/well in triplicates, 6-well
plates (Thermo Scientific, Cat # 14067) were incubated with 0
(control), 5, 10, 40, 80, 100 and 200 mg/ml Fe as USPIO (ferumoxy-
tol, Rienso, core diameter 10.8 ± 1.8 nm, hydrodynamic diameter
30.8 ± 0.1 nm) for 16 hrs. Concentrations expressed are of Fe con-
tained within USPIO and do not represent concentrations of parti-
cles. The J744 macrophages were washed three times with PBS
(BioWhittaker, Cat # 17516F) to remove non-phagocytosed
USPIO’s, collected by cell scraping and resuspended in 500 ml
PBS/2mM EDTA (BioWhittaker, Cat # 17-711E). Experiments utilis-
ing fresh cells were conducted immediately following PBS/EDTA
suspension, the samples transported on ice and light protected.
For fixation experiments, cells were washed and scraped as above
then fixed in 4% paraformaldehyde (Sigma-Aldrich, Cat #
HT501128-4L) for 15mins on ice. The cells were then spun, washed
twice with PBS then re-suspended in 500 ml PBS/2mM EDTA and
analysed within 24hrs (light-protected and stored at 4 C). Samples
for all experiments were prepared in triplicate. J774 phagocytosis
was confirmed on light microscopy (EVOS XL Core, USA) using
microbeads (Polysciences Inc., Cat # 18133-2) and USPIO internal-
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yielding Prussian blue.2.2. Fast field-cycling nuclear magnetic resonance experiments
Relaxation rate measurements were carried out using both a
0.25 T FFC-NMR benchtop relaxometer (SMARtracer, Stelar, Italy)
and a human whole-body, in-house built prototype 0.2 T FFC-
MRI system [24] which was used as a relaxometer (University of
Aberdeen EU Horizon 2020 programme). The RF coil used was a
home-built transmit/receive solenoid with an inner diameter of
approximately 10 mm, tuned to 8.5 MHz. Cell suspensions were
prepared as above to a total volume of 500 ml PBS/2mM EDTA
and analysed in glass test tubes (Samco, Cat # G050/18) at 21 C.
Both devices produced the same quantification of T1 and therefore
the results were comparable. On both devices, R1 dispersion mea-
surements were conducted using an identical non-imaging, satura-
tion recovery pulse sequence with 90 flip angle and 20 different
evolution fields selected logarithmically between 80 lT and 0.2 T
(3.4 kHz proton and 8.51 MHz Larmor frequency [PLF] respec-
tively). The evolution times were modified for each sample and
field, using 12 different values selected logarithmically from 0.1
to 4 times the T1 obtained from the previous measurement. The
acquisition bandwidth was set to 20 kHz for the FFC-MRI system
and 80 kHz for the relaxometer to account for lower field homo-
geneity, and in both cases the signal was recorded until it reached
the noise floor (Free Induction Decay (FID) length, approximately
50 ms for the FFC-MRI system and 5 ms for the relaxometer). In
total, the measurement time was less than 35 min per sample.
R1 of the test sample was measured at each evolution field, for
each of the triplicates. The average R1 of the three samples was
then calculated for each evolution field, and reported for each
USPIO exposure. The effect of USPIO exposure was measured sim-
ply by averaging the dispersion curve at each concentration, in
comparison with that of the control cell suspensions, which did
not show any R1 dispersion and could therefore be treated as a
constant baseline of approximately 0.3 s1 in the R1 dispersion
profiles. The dispersion curves obtained were analysed from 1.4
mT to 200 mT, a range that provided robust measurements on
both the benchtop and whole-body FFC devices. Spurious noise
occasionally generated gross outliers (These appeared at evolution
fields below 200lT (5 kHz PLF) due to the presence of non-
homogeneous environmental external magnetic fields), which
were removed manually before the triplicate measurements were
averaged and the contribution of non-USPIO relaxation was sub-
tracted from the data by subtracting the average relaxation rate
of the USPIO-free samples.
Since models are not readily available for USPIO relaxivity in
biological tissues, we compared the data to a reference T1 disper-
sion curve. This reference was obtained for each dataset (fresh or
fixed) by isolating the dispersion curve measured with the signal
with best SNR, and subtracting from it the average of the disper-
sion curve obtained for solutions without USPIO, in order to
remove the contribution of non-USPIO relaxation pathways. This
approach relies on the preservation of the shape of the disper-
sion curves for increasing concentrations of USPIO, which is
known to be an approximation but is fit for the purpose of this
proof-of-concept work. Once the reference was obtained, it was
compared to the dispersion curves of the samples by curve fit-
ting, taking a multiplication factor as the optimisation factor.
The quality of fit was measured using the Akaike Information
Criterion (AIC) [28] which provided average values of AIC of
54 ranging from 92 to 20. This single-parameter analysis
provided us with an estimate of the amplitude of the USPIOcontribution at different exposures, which appeared exponential
to a good approximation (AIC = 21 and 29 for fixed and fresh
cell data respectively).2.3. Imaging flow cytometry
Imaging flow cytometry was performed using the ImageS-
treamX Mark II (Luminex Corporation, USA), which combines the
quantitative power of flow cytometry and imaging feature of
microscopy, recording fluorescence intensities as well as bright-
field (BF) images of individual cells. Fixed and non-fixed J774 cells
were prepared as above and resuspended in 80 ml PBS/2mM EDTA
(pH 7.5) and measurements obtained using the ImageStreamX
Mark II INSPIRE acquisition software with magnification set to
60. ImageStream data were analysed using the proprietary anal-
ysis software IDEAS supplied by the manufacturer. The software
allows the exploration of series of image features derived from
each single cell based on automatically generated masks for each
imaging channel.
Single macrophages were selected by plotting the area feature
of brightfield channel 1 (BF1) versus the aspect ratio parameter
of the same BF channel, which is the ratio of minor axis to the
major axis of the applied mask and describes the shape of the mask
applied to the cells (Fig. 1A). Focused cells were then selected by
plotting the ‘Gradient RMS’ (RMS = root mean square) feature of
BF1 against the contrast parameter of BF1. Cells with high gradient
(>60) and high contrast value were more in focus and chosen for
further analysis. Features of focused cells were analysed using
custom-generated post-processing masks. Approximately 2000
focused cells were used in the analysis at each concentration.
Side Scatter (SSC) intensity was measured to assess cell granu-
larity in non-fixed cells only (Fig. 1A). Additional quantification of
USPIO-containing dark locules was performed using customised
masks on two BF channels (Fig. 1C). The ‘Adaptive Erode’ mask
on IDEAS then an ‘Intensity’ mask were applied to achieve this.
To exclude size variation between different cells, USPIO occu-
pied area was normalized to the entire area of the cells. Therefore
the area of the cells occupied by USPIO was calculated using the
formula: (USPIO areaBF1 + USPIO areaBF2)/(CELL areaBF1 + CELL
areaBF2) (Fig. 1D). The data was expressed as mean ± SEM of the
relative area of the cell occupied by USPIO.2.4. Colorimetric iron assay
Following plating, iron loading and washing as above, the PBS
was removed and the plates were frozen at 20 C pre-analysis.
Triton X-100 (Sigma-Aldrich, Cat # T8787-50ML, 200 ml at 0.01%)
solution was added directly to each well and the cells were har-
vested with a cell scraper. After micropipetting to encourage lysis,
the cell lysates were transferred to microtubes. Cell lysate (10 ml)
was removed from each sample for protein quantification using
an improved Lowry [29] -type assay (BIO-RAD DC protein assay,
Cat # 500-011).
A sensitive and validated colorimetric assay [30] utilising 2,20-
bipyridine (Fisher Scientific, Cat # 11492438) was calibrated and
used to quantify total iron content in remaining cell lysate. A stan-
dard curve was constructed by adding 10 ml of 10  103, 6  103,
4  103, 1.6  103, 0.64  103, and 0.26  103 M freshly pre-
pared solutions of ammonium iron (II) sulphate hexahydrate
(Sigma-Aldrich, Cat # 203505) to ‘control’ cell lysate (no USPIO
exposure). Absorbance at 520 nm was measured in a 96-well plate
on a Synergy HT (BioTek Instruments Inc., USA) plate reader. Iron
concentration was calculated by averaging triplicate samples,
expressed as ng/mg protein.
Fig. 1. Outline of the workflow used to delineate area occupied by USPIO and cell granularity, based on calculated cellular features on the Amnis ImageStreamX Mark II. A:
Single cells were selected by plotting area against aspect ratio assuming that most non-adherent macrophages were round in shape. Focused cells were selected by plotting
gradient against contrast and selecting cells with highest values of both features. SSC was measured to assess granularity. B: Both custom-generated (green) and the ‘adaptive
erode’ mask (no. 83) were used to identify USPIO-free intracellular area. USPIOs were identified using ‘intensity’ mask with the pixel intensity range (0–600). Intracellular
USPIOs were identified by selecting overlapping cell- and USPIO-occupied areas. C: Images from two BF channels were included in the final calculation, given the slight
difference between these images (white arrows). D: Calculation used to identify the relative areas of the cells occupied by USPIO. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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All data is shown as mean ± SEM. Independent sample t-test
was used to compare means, regression analysis to compare meth-
ods and Pearson r for correlations of data-sets. Statistical signifi-
cance was set at p < 0.05.3. Results
Table 1 shows the mean FFC-NMR derived average R1 across the
entire magnetic field tested for non-fixed and fixed cells, the mean
cytometry-derived non-fixed cell SSC and the mean cytometry-
derived USPIO area/total cell area for both non-fixed and fixed cell
suspensions, at all tested USPIO exposure concentrations. The
detection range (0.115 ± 0.118 ng/mg to 12.398 ± 0.233 ng/mg pro-
tein) of the colorimetric iron quantification assay of non-fixed cells
is shown for reference (p < 0.001 vs. control at all concentrations)
as the ‘absolute’ intracellular iron amount (basal cellular iron con-
tent and phagocytosed USPIO iron content) against which all com-
parisons were made. The uptake of USPIO by J774 cells is modelledin a curvilinear fashion, as detected by this technique (Fig. 2). As
seen in Table 1, all methods employed demonstrate ability to
detect incremental levels of USPIO exposure which was quantified
as intracellular iron.3.1. Fast field-cycling nuclear magnetic resonance detection of USPIO
USPIO was detected with excellent resolution at all concentra-
tions tested (p < 0.001 vs. control). There was good separation of
the average R1 NMR dispersion profiles of both non-fixed
(Fig. 3A) and fixed (Fig. 3B) USPIO-incubated cells compared to
control, over the range of field strengths used in the FFC-NMR
sequence and for all the USPIO exposure concentrations investi-
gated. The R1 dispersion curves obtained from FFC-NMR in fixed
cells showed the typical USPIO profile, with a peak at fields above
10 mT and a tail below (Fig. 3B); the position of the peaks appeared
to shift slightly towards lower magnetic fields in non-fixed com-
pared to fixed cells. There was strong positive correlation with col-
orimetric assay (r = 0.993 p < 0.001 non-fixed; r = 0.968 p = <0.001
fixed).
Table 1
Summary iron quantification with FFC-NMR, imaging flow cytometry and a conventional colorimetric assay; SSC = side-scattered light; *p < 0.05 vs. control; **p < 0.001 vs.
control. ‘Mean R10 was obtained by averaging R1 values at all tested evolution fields for each USPIO exposure concentration (the average of all the R1 values on the dispersion
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0 (control) 0.308 ± 0.014 0.439 ± 0.075 0.034 ± 0.001 26,860 0.044 ± 0.0004 0.115 ± 0.118
5 0.356 ± 0.013** 0.719 ± 0.026** 0.036 ± 0.001 32815** 0.046 ± 0.0003** 1.121 ± 0.045*
10 0.432 ± 0.016** 1.153 ± 0.024** 0.037 ± 0.001* 39573** 0.055 ± 0.0003** 2.074 ± 0.084*
40 0.706 ± 0.021** 2.348 ± 0.017** 0.069 ± 0.001** 69285** 0.072 ± 0.0003** 5.496 ± 0.134*
80 1.174 ± 0.031** 3.502 ± 0.147** 0.085 ± 0.001** 80967** 0.077 ± 0.0004** 8.421 ± 0.269*
100 1.239 ± 0.033** 5.174 ± 0.168** 0.090 ± 0.001** 82693** 0.078 ± 0.0003** 9.771 ± 0.100*
200 1.599 ± 0.041** 7.755 ± 0.257** 0.097 ± 0.001** 86373** 0.151 ± 0.0007** 12.398 ± 0.233*
Fig. 2. A: Iron quantification (from phagocytosed USPIO) using a 2,20-Bipyridine colorimetric assay as a standard reference. Cell iron uptake appears non-linear, best described
by the 3rd order polynomial y = 2E-06x3  0.0009x2 + 0.1616x + 0.3092; R2 = 0.999. All points represent triplicate mean ± SEM. B: Prussian blue visualised in J774
macrophages exposed to 40 mg/ml ferumoxytol USPIO and Perl stain; 400 magnification light microscopy. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
H. Abbas et al. / Journal of Magnetic Resonance 313 (2020) 106722 5Both fresh and fixed cells exhibited USPIO relaxation that
increased non-linearly with the particle concentration (Fig. 4A
and B, respectively). The mono-exponential model used appeared
to be a good approximation of the behaviour observed and pro-
vided a characteristic concentration of 108 (sigma = 25) and 210
(sigma = 140) mg/ml for fresh and fixed cells respectively. The
amplitude of the relaxation contribution due to USPIO also
increases significantly with cell fixation, turning from 1.26
(sigma = 0.14) to 6.4 (sigma = 3.2).3.2. Imaging flow cytometry detection of USPIO
Subjectively, more USPIO-containing cells were noted with
increasing USPIO exposure in BF images, with increasing capture
by the USPIO area mask (Fig. 5A). Mean USPIO area/cell area for
both non-fixed and fixed cells incremented with increasing USPIO
exposure, with sensitivity for detecting USPIO at exposures
10 mg/ml for non-fixed and 5 mg/ml for fixed cells (Table 1).
There was strong positive correlation with colorimetric assay
(r = 0.983, p < 0.001 non-fixed; r = 0.874, p < 0.05 fixed). Although
the trends were similar, there was a small but significant difference
in the detectable fraction of USPIO-occupied cell area with fixation,
with an overall increase of this parameter at all concentrations
inclusive of control samples (mean difference 20.2% ± 10.3% [range
13.4% to 55.6%]; p < 0.001 for all). Best fit was achieved using a
simple linear regression model (R2 = 0.763 non-fixed; 0.967 fixed;
Fig. 5B). In non-fixed cells SSC intensity reliably detected USPIOrelative to control cells at exposures 5 mg/ml (p < 0.001 for all
concentrations). This also correlated positively with colorimetric
assay (r = 0.967 p < 0.001) but best fit could be expressed with a
curvilinear model (R2 = 0.994; Fig. 5B).
4. Discussion
4.1. Key findings
The main finding of this proof-of-concept work shows that FFC-
NMR can detect and quantify USPIO contrast using T1 dispersion
information. FFC-NMR is capable of detecting cellular iron content
at approximately 1.12 ng/mg cell protein (at the lowest tested
exposure of 5 mg/ml USPIO) and resolves this from a control cell
lysate that had not been exposed to USPIOs. These large T1 differ-
ences seen in the low magnetic field domain may allow us to
exploit efficient T1-based contrast through the use of a gradient
echo pulse sequence with FFC-MRI, since FFC enables ‘‘tuning” of
the pulse sequence to specific features in the relaxivity curve, by
suitable choice of the evolution field.
4.2. The effects of chemical fixation
The 5-fold increase observed in the USPIO contribution to the
relaxation rate in fixed vs. fresh cells, may be attributed to the
enhanced access of water molecules to sites of USPIO relaxation,
since formaldehyde fixation is known to alter cell membranes,
Fig. 3. R1 dispersion curves of non-fixed (A) and fixed (B) J774 cell suspensions
exposed to 0–200 mg/ml USPIO. Each data point represents a mean of
triplicates ± SEM.
Fig. 4. Effect of increasing macrophage USPIO exposure concentration on the
average relaxivity of the USPIO compared to a reference NMRD profile in fresh (A)
and fixed (B) cells. The average ratio between the NMRD profile and the reference
profile shows that the relaxivity of internalised USPIO saturates with concentration,
which is expected, but this effect is almost twice as important in fresh cells.
6 H. Abbas et al. / Journal of Magnetic Resonance 313 (2020) 106722increasing their porosity and facilitating water exchange with the
extracellular medium. Formaldehyde fixation has therefore
increased the sensitivity of USPIO detection in our experiment.
The non-linearity of the USPIO contribution with its concentration
is likely due to aggregation of the nanoparticles in cells, which
tends to quench its effect. This effect seems less pronounced in
fixed cells, which improved the detection range of USPIO by FFC-
NMR. Strijker et al. [31] described a three-compartment model
for T1-relaxation time constant of systems with internalised para-
magnetic contrast agents, employing a voxel containing an extra-
cellular, cytoplasmic and vesicular compartment (with particular
focus on the subcellular compartment). Their calculations mirrored
those demonstrated experimentally. The multiexponential T1
relaxation and non-linear contrast agent dependence of R1 for con-
trast agent-loaded-cells was explained by relaxivity-‘quenching’,
observed when contrast agents are internalised due to limited
water exchange consequent to contrast agent entrapment in sub-
cellular compartments.
Fixation on the other hand causes major changes in tissue bio-
physical properties. It reduces ADCex (the apparent diffusion coef-
ficient of water in the extracellular space) and increases mean
intracellular residence time (Ƭ = 1/kie) [32]. Formaldehyde itself
forms hydrates in aqueous solution that cross link a portion of
the molecule into a polymeric matrix, slowing molecular motion
and reducing water ADC and proton T2. Interaction with aquaporin
channels has also been suggested, altering water mobility [32].
4.3. The effects of USPIO clustering
Clustering also affects USPIO relaxivity and is important to con-
sider when interpreting results. In early clinical experiments utilis-
ing SPIO assessing hepatic and splenic uptake on MRI, T1 and T2increased linearly with increasing SPIO exposures in agar gel phan-
toms, with similar effects quantified on clinical imaging (fast SE for
T2, SPGR for T1, SPGR for T2*) [33]. The effect of clustering was more
important for T2* relaxation effect caused by SPIO than for
homogenous biodistribution. T1 was more pronounced in spleen
where clusters are smaller, and T2* signal dropout smaller due to
the same. Water molecules in the spleen can diffuse in the vicinity
of SPIO clusters more frequently than in the liver, due to the larger
number and smaller size of SPIO clusters.
Simon et al. [34] demonstrated that USPIO compartmentalisa-
tion by monocytes changes proton relaxivity, with higher T1 and
T2 values of free extracellular USPIO in Ficoll solution at both
1.5 T and 3 T. At 3 T however, differences in T1 relaxivities of USPIO
were smaller than 1.5 T, while differences in T2 were similar.
Increasing R1 with USPIO dose was attributed to increasing interac-
tion between iron oxide and water, while increased R2 due to
decrease in water coefficient.
The non-linear relationship observed between relaxation rate
and USPIO exposure however will have important implications
for being able to separate signals from USPIO remaining in the
extracellular space, from those internalised within phagocytic
macrophages [34], as the motion of water protons differs signifi-
cantly in the extracellular versus intracellular milieus [35,36]. Pre-
viously published data reports that USPIO in solution has higher T1
and T2 than cells with completely internalised USPIO [34,37].
4.4. Intracellular USPIO and flow cytometry
Whilst imaging flow cytometry detection by traditional side
scatter was comparable in sensitivity to FFC-NMR, the USPIO-
occupied area was only sensitive at exposures 10 mg/ml USPIO
Fig. 5. Imaging flow cytometric analysis of USPIO-exposed non-fixed and fixed cells. A: Macrophage imaging and localisation of intracellular USPIO aggregates (highlighted in
green). B: The relative USPIO-occupied cell area as calculated by custom-generated image masks, and SSC intensity reflecting cell granularity (expressed as mean ± SEM), both
increasing with higher USPIO exposure, based on intracellular iron amounts quantified colorimetrically (mg iron/ mg protein). Regression lines shown for all three. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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ventional technique for iron quantification, it does uniquely pro-
vide quantifiable data on cell complexity [38,39] (reflected in the
increasing SSC with higher USPIO exposures) as well as imaging
data demonstrating an increase in quantifiable dark locules. It also
reassuringly demonstrated the internalisation of the USPIOs by
macrophages in vitro. While this provided an excellent verification
of the increase in cellular uptake of USPIOs in intact cells, the level
of sensitivity is inferior to the FFC-NMR method and imaging
cytometry cannot be translated into in vivo methods to detect
inflammation.
4.5. Justification for the use of T1 and low magnetic fields
Early work assessing post-mortem samples of pathologically
iron-overloaded (majority with beta thalassemia major) human
myocardium ex-vivo with MR relaxometry, studied tissue contain-
ing much higher concentrations of iron [40]. Here myocardial iron
concentration ranged between 0.18 and 53.4 mg/g dry weight and
expressed a curvilinear relationship with T2*. Gradient echo T2*
multiecho techniques can indeed rapidly assess for iron overload
in vivo in transfusion-dependent beta thalassemia patients [41].
These techniques however are useful for identifying and monitor-
ing frank iron overload syndromes [42]. Normal myocardial iron
concentration have been reported to be 0.34 mg/g dry weight
(range 0.29 – 0.47 mg/g). This raises an important consideration
for the required sensitivity of NMR relaxometric or imaging meth-
ods in discerning differences between normal and USPIO-loadedinflamed tissue, as well as the localising ability of these techniques
which is relevant to focal pathologies like coronary artery disease.
The limitations of analysing pixel maps of T1 and T2 are well rec-
ognized [43–45]. T2* relaxometry for quantitative analysis is gener-
ally limited by large scale field inhomogeneity with potential
signal loss and R2* over-estimation. Very short T2* values may be
error prone and shorter inter-echo times can also over-estimate
R2*. T2* negative-signal imaging is associated with artefacts at
the blood-pool to myocardium interface which need careful exclu-
sion when selecting myocardial regions of interest. Blooming arte-
facts also commonly arise from nearby organs with high iron
uptake, or from blood pool iron [46]. The reversible relaxation rate
T2* is usually measured to detect compartmentalized SPIOs sensi-
tively [47]. T2* relaxation rate is however also influenced bymacro-
scopic susceptibilities that arise from air-tissue interfaces (e.g.
lung-liver interface). These susceptibilities enhance signal decay,
increasing linearly with the field strength leading to overestimated
relaxation rates or the obscuring of small concentrations of SPIO-
labelled [48]. The very short T1 of USPIO-associated tissue has been
a significant deterrent in its clinical use for USPIO quantification at
conventional fixed fields. A number of positive contrast techniques
relying on pulse sequence modifications have been described how-
ever [49].
T2 has limitations in detecting low iron concentrations where T2
or T2* durations are too short to be imaged. Newer techniques such
as sweep imaging with Fourier transformation (SWIFT) [50] may
overcome this limitation as demonstrated at 9.4 T in the detection
of SPIO-labelled embryonic stem cells injected into murine hearts.
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sition delay are unique features of SWIFT which make it particu-
larly well suited for imaging frequency-shifted resonances and
for minimizing signal loss from T2*-induced dephasing.
Whereas high field aims to improve image resolution and
increase SNR, on the other hand cost, magnet size, tissue heating
and safety are major concerns. Versluis et al. [51] report generally
good tolerance at 7 T human scans with 3% of volunteers reporting
discomfort, most commonly dizziness while moving into/out of the
magnet, high noise levels and perception of a metallic taste. In
addition, higher magnetic fields invite more artefact particularly
frommetallic prostheses. There is increased chemical shift artefact,
higher specific absorption rate (SAR), B1 inhomogeneity and spatial
variation of flip angles [52].
Stroh et al. [53] highlighted some of these limitations when
monitoring the biodistribution of very small iron oxide
nanoparticle-laden (VSOP, 9 nm diameter, smaller than USPIO)
grafted stem cells in vivo (stereotactically injected into rat stria-
tum). T2* signal was detected from approximately 1000 grafted
VSOP-loaded cells in transplantation sites but this was performed
at 17.6 T – not currently possible in humans. The proposed advan-
tage of the high field is the higher equilibrium magnetisation giv-
ing higher intrinsic SNR, with changes in magnetic susceptibility of
iron particles leading to more pronounced signal reduction in the
grafted cells than at lower field strengths. The caveat was the high
sensitivity to artefact particularly when remedied with steady-
state free precession (SSFP) techniques in inhomogenous media
or if the object was moving. A low magnetic field was proposed
to be adequate however for the detection of the bulk motion of
several thousand cells.
Low fixed magnetic field clinical imaging is gaining consider-
able interest at present [54] due to potential cost-effectiveness.
The reduced SAR and susceptibility effects resulting from the use
of a lower magnetic field has clear application for imaging in the
vicinity of metallic implants. This can translate into higher patient
safety and clinical utility – notably reducing the hazard from the
‘missile effect’ and RF heating. The reduced heating/SAR would
allow higher flip angles to maximise CNR. Low field MRI is also
much less sensitive to chemical shift artefacts [26]. The above
strengths are currently paving the way for the development of car-
diac MR-guided interventional devices [55].
4.6. Justification for the use of FFC-MR
FFC-MR advantageously increases the available frequency
(field) range permitting faster scanning, as the detection field is
constant, and without the RF apparatus requiring adjustment for
a varying relaxation field. Systematic errors in T1 caused by non-
homogenous T1 RF fields are reduced as the perturbation of the
sample occurs by a rapid jump of the external field B0 and not by
an RF pulse.
T1 measurements on conventional, fixed-field NMR or MRI
devices can only report on a single characteristic time of molecular
motion. FFC however allows access to several decades of motional
dynamics [56], typically from tens of nanoseconds to several mil-
liseconds. Measurements of T1 dispersion with the magnetic field
strength, allow quantitative insight into the nature of molecular
motion and are exploited to determine structural [57–59]. These
time scales correspond to structures ranging in size from tens of
nanometres up to several micrometres, highly relevant to the
study of biological tissues. For example, the quadripolar dip
observed in FFC-MR T1-dispersion curves is a consequence of
cross-relaxation from dipole to quadripole nuclei, and is inaccessi-
ble by conventional MRI [60–62]. This can translates to the study of
large molecules and protein structures e.g. in thrombus and carti-
lage [25,63].We have recently reported on the first human size FFC-MR
prototype in the world which will be well suited for such clinical
applications. This breakthrough in MRI technology can access
magnetic fields from 50 lT to 0.2 T, thereby exploring almost four
decades of molecular-dynamics time scales, from 0.5 ms to
100 ns.
Experiments on phantoms using our FFC-MR prototype suc-
cessfully allowed differentiation between cross-linked bovine
serum albumin (BSA) and manganese chloride solutions simply
by clustering over T1 dispersion information [24] shapes of the dis-
persion curves provided by the two compounds. Determining sam-
ple concentration was also possible using the average T1 value.
The relationship between the linearity of the dispersion amplitude
and the concentration of relaxing agents demonstrated that FFC-
MRI can differentiate materials easily as well as provide quantita-
tive information about their composition. Accurate characterisa-
tion of the dispersion of biological tissues could lead to
quantitative mapping of tissue-specific T1. Furthermore dispersion
curves may function as ‘biomarkers’ for certain pathologies and
resolve differences in tissue not detected by conventional MRI.
Previous work by our group and others [25,26,60,61,63–71] inves-
tigating tissue biopsies, showed potential biomarkers in a variety
of pathologies that can now be investigated in vivo, using endoge-
nous contrast FFC-MRI technology therefore has major potential to
complement conventional MRI scanners in clinical diagnostics.
Clinical imaging using FFC-MR has already been demonstrated in
a study of acute stroke [72]. The current work explores a further
FFC-MR avenue: the role of exogenous USPIO-based contrast, as
proof-of-principle and stepping stone for the MR/MRI study of
inflammation in vivo.4.7. Study limitations
The FFC-NMR scanners could only analyse one sample at a
time and therefore the staggering of fresh cell suspensions could
have affected cell viability and possibly influenced T1 relaxation
time. To mitigate this, the samples were refrigerated at 4 C
before their scan to minimise any such possibility pending scan-
ning. Cell viability was only confirmed with light microscopy. It is
possible that a degree of cell lysis with the passage of time could
have resulted in extracellular, free USPIO, which may have
affected FFC-NMR T1 dispersion data. The imaging capability of
our cytometric technique, however, provided an additional check
of the integrity of cell membranes in both non-fixed and fixed
samples.
The FFC-MRI scanner can exhibit relatively large field instabili-
ties during operation, com-pared to fixed-field MRI. Nevertheless,
post-acquisition corrections can be used to obtain clinically
robust images from T1 dispersion data [73]. Our future work
endeavours to develop FFC-MR in vivo assessment and imaging
utilising USPIO.5. Conclusion
In this work we used a cell-based model for the in vitro detec-
tion of intra-cellular USPIO by FFC-NMR as a proof of principle
for future translation towards imaging using FFC-MRI. We demon-
strated for the first time that FFC-NMR is capable of quantitative
assessment of intra-cellular USPIO, with levels of detection directly
relevant to biological applications. The use of FFC-MRmay comple-
ment clinical diagnostics by accessing relaxometry features not
readily available at higher field strengths or in fixed fields. Further
work is required to develop this technology for the in vivo assess-
ment of inflammation and/or unlock its imaging potential with
USPIO.
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